A Multi-Center, Prospective, Observational Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab

This observation study is a large-scale, prospective, and multi-organ observation study to observe the improvement effect of the self-evaluation results (PRO) of erosive gastroesophageal reflux disease at least 4 to 8 weeks after administration of Fexuclue Tab.

Inclusion Criteria:Adult men and women aged 19 to 75 years of age at the time of registration.A patient with erosive gastroesophageal reflux disease who is scheduled to administer Fexuclue Tab. for the first time based on the medical judgement of the researcher based on the medication authorization.A person who voluntarily agrees to participate in this observation study and signed the informed consent form.Exclusion Criteria:A person who falls under the prohibition of administration according to the permission for Fexuclue TabletPatients with hypersensitivity to the components of Fexuclue tablet or Fexuclue tablet and a history thereofPatients undergoing Atazanavir, Nelfinavir or Lilpivirin-containing preparationsPregnant and lactating womenPatients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabortionA person who participates in another clinical trial and is administering (applying) clinical trial drugs or clinical trial medical devices;In addition to the above, a person who has determined that the researcher (the doctor in charge) is not suitable for participation in this observation study